High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1

Biochemical and Biophysical Research Communications

Volumn 421, Issue 4, 2012, Pages 850-854

  Zhou, Fangye ^a   Zhou, Jian ^a   Ma, Lei ^a   Song, Shaohui ^a   Zhang, Xinwen ^a   Li, Weidong ^a   Jiang, Shude ^a   Wang, Yue ^b   Liao, Guoyang ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Highly pathogenic avian influenza (HPAI) viruses; Reverse genetics; Vero cells; Yield and stability

Indexed keywords

VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; FEMALE; HEMAGGLUTINATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VERO CELL;

ANIMALS; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; REASSORTANT VIRUSES; VACCINES, ATTENUATED; VERO CELLS; VIRUS CULTIVATION;

AVIAN INFLUENZA VIRUS; GALLUS GALLUS;

EID: 84861224171     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.101     Document Type: Article

References (36)

1. Available from: <>, 2011 (accessed 29.11.11). http://www.who.int/influenza/human_animal_interface/avian_influenza/archive/en/index.html.
2. Uyeki T.M. Global epidemiology of human infections with highly pathogenic avian influenza A(H5N1) viruses. Respirology 2008, 13:S2-S9.
3. Wu J., Zhang F., Wang Y., et al. Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. PLoS One 2010, 5:e15825.
4. Du N., Wang Y., Shu Y., et al. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J. Virol. 2010, 84:7822-7831.
5. Subbarao K., Luke C. H5N1 viruses and vaccines. PLoS Pathog. 2007, 3:e40.
6. Govorkova E.A., Webby R.J., Humberd J., et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 2006, 194:159-167.
7. Collin N., De Radiguès X. The World Health Organization H1N1 Vaccine Task Force, vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009, 27:5184-5186.
8. World population prospects: the 2008 revision, 2009. Available from: <>. http://www.who.int/pmnch/topics/2008_populationstats/en/.
9. Isoda N., Sakoda Y., Kishida N., et al. Pathogenicity of a highly pathogenic avian influenza virus, A/chicken/Yamaguchi/7/04(H5N1) in different species of birds and mammals. Arch. Virol. 2006, 151:1267-1279.
10. Wright P.E. Vaccine preparedness - are we ready for the next influenza pandemic?. N. Engl. J. Med. 2008, 358:1540-1543.
11. Nerome K., Kumihashi H., Nerome R., et al. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model. Dev. Biol. Stand. 1999, 98:53-63.
12. Hu A.Y., Tseng Y., Gu A., et al. Production of inactivated influenza H5N1 vaccines from MDCK cells in Serum-Free medium. PLos One 2011, 6:e14578.
13. Genzel Y., Olmer R.M., Schäfer B., Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006, 24:6074-6087.
14. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 2009, 8:607-618.
15. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 2010, 12:21-30.
16. Howard M.K., Kistner O., Barrett P.N. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 2008, 389:569-577.
17. Kistner O., Howard M.K., Spruth M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25:6028-6036.
18. G. Liao, D. Fan, M. Sun, W. Li, J. Zhou, Y. Zhang, The application of a Vero cell adapted influenza A H3N2 strain. State intellectual property office of P.R.C patent, 2009; patent number: 200910094223.8. Available from: <>. http://www.soopat.com/Patent/200910094223.
19. Shu Y., Yu H., Li D. Lethal avian influenza a (H5N1) infection in a pregnant woman in Anhui province, China. N. Engl. J. Med. 2006, 354:1421-1422.
20. Dong J., Matsuoka Y., Maines T.R., et al. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respir. Viruses 2009, 3:287-295.
21. Zhang Y., Lin X., Zhou H., Wang G., et al. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLos One 2010, 5:e9167.
22. Zhang Y., Shu Y., Wang Y., et al. Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem. Biophys. Res. Commun. 2009, 387:405-408.
23. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97:6108-6113.
24. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
25. Khurana S., Larkin C., Verma S., et al. Recombinant HA1 produced in E.Coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 2011, 29:565756-565765.
26. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-Cell-Dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 2001, 75:5141-5150.
27. Garten W., Linder D., Rott R., Klenk H.A. The cleavage site of the hemagglutinin of fowl plague virus. Virology 1982, 122:186-190.
28. Keitel W., Groth N., Lattanzi M., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28:840-848.
29. Ehrlich H.J., Müller M., Helen M.L., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 2008, 358:2573-2584.
30. Horimoto T., Murakami S., Muramoto Y., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 2007, 366:23-27.
31. Chen L., Davis C.T., Zhou H., Cox N.J., Donis R.O. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 2008, 4:e1000072.
32. Jackson S., Hoeven N.V., Chen L., et al. Reassortment between avian H5N1 and human H3N2 influenza viruses in Ferrets: a public health risk assessment. J. Virol. 2009, 83:8131-8140.
33. Li C., Hatta M., Nidom C.A., et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4687-4692.
34. Tseng Y., Hu A.Y., Huang M., et al. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 2010, 6:e24057.
35. The European Agency for the Evaluation of Medical Products, Human Medicines Evaluation Unit, Note for guidance on harmonization of requirements for influenza vaccines, (1997) 1-18.
36. Liu Y., Liu X., Fang J., et al. Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Vaccine 2010, 29:183-190.